United Therapeutics (NasdaqGS:UTHR) reported full Phase 3 TETON-2 trial data for nebulized Tyvaso in idiopathic pulmonary ...
Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...
Executives from Contineum Therapeutics (NASDAQ:CTNM) outlined the company’s clinical priorities and upcoming catalysts during a presentation at the Leerink Global Healthcare Conference, emphasizing a ...
Baseimmune unveils a new multi-pathway immunotherapy strategy, applying its computational protein design platform to develop next-generation therapies for fibrosis. Fibrosis is driven by complex and ...
IPF has an insidious onset. It often presents with persistent dry cough associated with worsening breathlessness and progressive decline in one's exercise capacity. Hemoptysis (coughing up blood) is ...
What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...
Orphan status in the U.S. can confer clinical-trial tax credits, user-fee exemptions, and up to seven years of post-approval market exclusivity for rare-disease programs. As a deuterated form of ...
The MarketWatch News Department was not involved in the creation of this content. CHICAGO, Dec. 22, 2025 /PRNewswire/ -- The Prognostic Lung Fibrosis Consortium (PROLIFIC), a collaborative consortium ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...
Forbes contributors publish independent expert analyses and insights. Robert Glatter is a New York-based physician covering public health. This article is more than 6 years old. Idiopathic pulmonary ...
What is idiopathic pulmonary fibrosis (IPF)? Idiopathic pulmonary fibrosis (IPF) is a debilitating and fatal lung disease that affects approximately 3 million people worldwide. Despite the condition ...
Mendelian randomization revealed a potential protective role of IPF against large artery atherosclerosis stroke, but no significant links with other cardiovascular diseases. The study suggests ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results